Agoracom Blog Home

Posts Tagged ‘CSE’

« Older Entries
Newer Entries »

Tetra Bio-Pharma Announces the Initiation of its Phase I Trial of dried Cannabis $TBP.ca

Posted by AGORACOM-JC at 8:45 AM on Thursday, February 23rd, 2017

Tbp large

  • Announces launch of its Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers
  • Phase I clinical research is a classical pharmaceutical study in the development of a new drug. The trial activities will occur over a 3 to 4-month period and involve site initiation, subject recruitment and enrolment, a single daily ascending dose phase and a 7-day multiple daily ascending dose phase, followed by study termination

OTTAWA, ONTARIO–(Feb. 23, 2017) – PhytoPain Pharma (PPP), a subsidiary of Tetra BioPharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce the launch of its Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers.

The Phase I clinical research is a classical pharmaceutical study in the development of a new drug. The trial activities will occur over a 3 to 4-month period and involve site initiation, subject recruitment and enrolment, a single daily ascending dose phase and a 7-day multiple daily ascending dose phase, followed by study termination. Algorithme Pharma has already begun recruiting subjects for the Phase I trial. This study is a pivotal safety trial as it will allow Tetra to understand the adverse effects of smoking Cannabis and associate the outcomes, such as cognitive function, to plasma levels of THC and CBD. The study will provide Tetra with the data necessary to discuss with Health Canada and FDA the potential risks in patient populations and discuss marketing requirements for specific indications.

The pharmacokinetic profile and safety data generated by the Phase I trial will allow Tetra to finalize the design of its Phase II-III clinical trial that will assess the safety and efficacy of PPP001 in cancer patients with uncontrolled pain. PPP001 is being developed for cancer patients with moderate-to-severe pain and that are not adequately controlled with the standard of care. Approximately 50% of cancer patients suffer from pain and more than 600,000 of these patients suffer from moderate-to-severe pain. In the USA, there are over 4 million cancer patients and this pain market is valued at over $5 billion USD.

“We are very pleased to announce that the start of the Phase I clinical trial activities as this keeps the company on track in its development of PPP001″, commented Mr, Andre Rancourt. “With PPP001 and the mucoadhesive AdVersa® controlled-release tablet, Tetra is positioning itself to become a major player in the cancer pain therapy market,“ added Mr. Rancourt.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

 

Tags: , , , ,
Posted in All Recent Posts, Featured, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Announces the Initiation of its Phase I Trial of dried Cannabis $TBP.ca

Fairmont (TSX-V: FMR) Receives Short Extension For Grabasa Acquisition $FMR.ca

Posted by AGORACOM-JC at 11:40 AM on Wednesday, February 22nd, 2017

  • Received an extension to complete the payment for Granitos de Badajoz  until March 8, 2017 from the Spanish Court in Badajo
  • “We have been working diligently with a European based funding group and they are in the final stages of completing the necessary documentation,” states Michael Dehn, President and CEO of Fairmont Resources…”

VANCOUVER, BRITISH COLUMBIA–(Feb. 22, 2017) – Fairmont Resources Inc. (“Fairmont”) (TSX VENTURE:FMR) is pleased to announce it has received an extension to complete the payment for Granitos de Badajoz (“Grabasa”) until March 8, 2017 from the Spanish Court in Badajoz.

“We have been working diligently with a European based funding group and they are in the final stages of completing the necessary documentation,” states Michael Dehn, President and CEO of Fairmont Resources. “While there can be no guarantee of success until this process is completed, this short extension was required to secure the Grabasa assets while finalizing the required logistics and paperwork for financing.”

Upon receipt of clearance documentation Fairmont will provide an update to all stakeholders, expected to be in less than a week, on the status of funding for Grabasa.

About Fairmont Resources Inc.

Fairmont Resources Inc. is a rapidly growing industrial mineral and dimensional stone company trading on the Toronto Venture Exchange symbol FMR.

Fairmont’s Quebec properties cover numerous occurrences of high-grade titaniferous magnetite with vanadium, with the Buttercup property having a permit to quarry dense aggregate. Where these occurrences have been tested they have display exceptional uniformity with respect to grade. Fairmont also controls three quartz/quartzite properties, with the Forestville property having independent end user testing confirming the suitability of quartzite from Forestville for Ferro Silicon production. Fairmont is also in the process of acquiring the assets of Granitos de Badajoz (GRABASA) in Spain which includes 23 quarries and a 40,000 square metre granite finishing facility that has produced finished granite installed across Europe.

On behalf of the Board of Directors,

Michael A. Dehn, President and CEO, Fairmont Resources Inc.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Fairmont cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Fairmont’s control. Such factors include, among other things: risks and uncertainties relating to Fairmont’s ability to complete the proposed private placement financing, limited operating history and the need to comply with environmental and governmental regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, Fairmont undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Michael A. Dehn
President and CEO, Fairmont Resources Inc.
647-477-2382
[email protected]
www.fairmontresources.ca

Doren Quinton
President QIS Capital
250-377-1182
[email protected]
www.smallcaps.ca

 

Tags: , , ,
Posted in Fairmont Resources | Comments Off on Fairmont (TSX-V: FMR) Receives Short Extension For Grabasa Acquisition $FMR.ca

Chile’s SQM sees 8-10% growth in lithium demand this year $NAM.ca $DGO.ca $BFF.ca $SX.ca $FMR.ca

Posted by AGORACOM-JC at 11:22 AM on Wednesday, February 22nd, 2017
  • “The prices in the lithium market and the growth in demand have been quite relevant in recent years. We expect growth in demand for this product of between 8 and 10 percent,” Illanes said.

Feb 19 Chile’s SQM expects demand for lithium to grow between 8 percent and 10 percent this year and is working to improve financial performance by 2020, an executive told local paper El Mercurio on Sunday.

SQM, one of the world’s biggest producers of lithium and iodine, has been trying to consolidate its position with investments abroad.

In 2020 SQM expects annual earnings before interest, taxes, depreciation and amortization (EBITDA) of $1 billion. Currently quarterly EBITDA is less than $200 million, Gerardo Illanes, vice president of finances, told the newspaper.

“The prices in the lithium market and the growth in demand have been quite relevant in recent years. We expect growth in demand for this product of between 8 and 10 percent,” Illanes said.

SQM plans to invest $100 million to increase its production capacity this year, which combined with its capital injection in Argentina would lead to a total investment of around $300 million, he said.

Illanes said SQM would not have a problem financing its projects although he did not rule out tapping debt markets. (Reporting by Fabián Andrés Cambero; Writing by Caroline Stauffer; Editing by Jeffrey Benkoe)

Source: http://www.reuters.com/article/sqm-demand-idUSL1N1G407H

Tags: , , , ,
Posted in Durango Resources, Fairmont Resources, Nevada Energy Metals, Small Cap Lithium Stocks | Comments Off on Chile’s SQM sees 8-10% growth in lithium demand this year $NAM.ca $DGO.ca $BFF.ca $SX.ca $FMR.ca

Durango Announces Acquisition of Bentonite, Perlite and Zeolite Projects in BC $DGO.ca

Posted by AGORACOM-JC at 5:12 PM on Thursday, February 16th, 2017

Logo

  • Acquired a 100% interest in British Columbia industrial mineral claims covering five projects which include bentonite, perlite, and zeolite BC MINFILE occurrences

Vancouver, BC / February 16, 2017 – Durango Resources Inc. (TSX.V-DGO), (the “Company” or “Durango”) is pleased to announce that it has acquired a 100% interest in British Columbia industrial mineral claims covering five projects which include bentonite, perlite, and zeolite BC MINFILE occurrences.

One zeolite project is located adjacent to the recently announced acquisition by Ashburton Ventures (TSX.V-ABR), as outlined in the Ashburton news release dated January 30, 2017. The Durango acquisition overstakes the irregular-shaped mining lease of the Z-1 zeolite quarry/mine near Cache Creek, British Columbia, being acquired by Ashburton and is within approximately 800 metres of the centre of the mining lease.

The second zeolite project is also located in the Cache Creek area, along Hwy 1/Hwy 97. Durango is acquiring 100% of an occurrence of zeolite, known as Perry Ranch, reported in 2011. The acquisition covers an area that is reported as “…approximately 300 metres long and contains several layers to 10 metres depth.” (1)

The third claim block covers the Uncha Lake perlite occurrence (2), and is located near Burns Lake, British Columbia. Past work discusses the occurrences as a perlite unit interbedded within porphyritic rhyolite layers which are reported to be 2.0 – 9.0 metres thick. The perlite is light grey to pale greenish-grey with some perlitic glass occurrences. The perlite generally dips shallowly to the south and is 7.6 to 23.9 metres thick. The report goes on to state that historical reports indicate that in 1955, nineteen trenches were exposed at approximately 45 metre intervals, exposing 2,400 metres of bedrock. Six perlite layers along a zone 850 metres long and 500 metres wide were exposed. (2) (3)

Durango is also acquiring the past-producing Princeton Bentonite occurrence, near Princeton, British Columbia, which was historically reported to have produced 771 tonnes of bentonite between 1926 and 1944. (4)

Three additional titles adjacent to the Dot Mordenite BC MINFILE occurrence near Merritt, British Columbia, which has been reported as a potential zeolite prospect, area also part of this land package. (5) (6)

Further details on these acquisitions will be provided as they become available.

About Zeolite, Perlite, and Bentonite

Zeolites are microporous aluminosilicate minerals commonly used as commercial absorbents and catalysts in the petrochemical industry as well as detergents. They are also widely used as ion-exchange beds in domestic and commercial water purification, softening, and aquaculture applications. Zeolite is also used in growing media, animal feed supplements, composting, and alternative medicine.

Perlite is an amorphous volcanic glass, typically formed by the hydration of obsidian. It has the unusual property of greatly expanding when heated sufficiently. Perlite is primarily used in construction in the production of lightweight plasters, mortars and cement formulations, and in well cements for oil and gas drilling. In horticulture, perlite can be used as a soil amendment or alone as a medium for hydroponics or for starting cuttings.

Bentonite is an absorbent aluminum phyllosilicate clay consisting mostly of montmorillonite. The main uses of bentonite are for drilling mud, binder (e.g. foundry-sand bond, iron ore pelletizer), purifier, absorbent, and as a groundwater barrier. Bentonite is also used in some forms of alternative medicine.

Durango has agreed to pay 1,000,000 common shares to an arm’s length vendor for the 100% acquisition of all projects subject to TSX Venture Exchange approval.

The technical contents of this release were approved by Case Lewis, P.Geo., a Qualified Person as defined by National Instrument 43-101. The property has not yet been the subject of a National Instrument 43-101 report.

References

  1. (1)ARIS (BC Assessment Report Database) Report 33072
  2. (2)ARIS (BC Assessment Report Database) Report 20026
  3. (3)BC MINFILE 093F 026: “UNCHA LAKE”
  4. (4)BC MINFILE 092HSE151: “PRINCETON BENTONITE”
  5. (5)BC MINFILE 092ISW108: “DOT MORDENITE”
  6. (6)ARIS (BC Assessment Report Database) Report 30607

About Durango

Durango is a natural resources company engaged in the acquisition and exploration of mineral properties. The Company has a 100% interest in the Mayner’s Fortune and Smith Island limestone properties in northwest British Columbia, the Decouverte and Trove gold properties in the Abitibi Region of Quebec, and certain lithium properties near the Whabouchi mine, the Buckshot graphite property near the Miller Mine in Quebec, the Dianna Lake silver project in northern Saskatchewan, the Whitney Northwest property near the Lake Shore Gold and Goldcorp joint venture in Ontario, as well as three sets of claims in the Labrador nickel corridor.

For further information on Durango, please refer to its SEDAR profile at www.sedar.com.

Marcy Kiesman, Chief Executive Officer

Telephone: 604.428.2900 or 604.339.2243

Facsimile: 888.266.3983

Email: [email protected]

Website: www.durangoresourcesinc.com

Forward-Looking Statements

This document may contain or refer to forward-looking information based on current expectations, including, but not limited to the development, commencement and completion of future exploration or project development programs and the impact on the Company of these events. Forward-looking information is subject to significant risks and uncertainties, as actual results may differ materially from forecasted results. Forward-looking information is provided as of the date hereof and we assume no responsibility to update or revise them to reflect new events or circumstances. For a detailed list of risks and uncertainties relating to Durango, please refer to the Company’s prospectus filed on its SEDAR profile at www.sedar.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

Tags: , , ,
Posted in Durango Resources, Small Cap Lithium Stocks | Comments Off on Durango Announces Acquisition of Bentonite, Perlite and Zeolite Projects in BC $DGO.ca

UPDATE: Tetra Bio-Pharma Reports Approval by Health Canada of its Phase I Trial of dried Cannabis $TBP.ca

Posted by AGORACOM-JC at 2:24 PM on Thursday, February 16th, 2017

Tbp large

  • Tetra has worked with Algorithme Pharma, an Altasciences company, for the preparation of the Clinical Trial Application (CTA) for the conduct of a Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers

OTTAWA, ONTARIO–(Feb. 16, 2017) – PhytoPain Pharma Inc. (PPP), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that the Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis.

Tetra has worked with Algorithme Pharma, an Altasciences company, for the preparation of the Clinical Trial Application (CTA) for the conduct of a Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers. The CTA was submitted to Health Canada and the research ethics review board in December 2016. On January 3, 2017, the clinical trial received approval from the Institutional Review Board. TPD issued a Letter of Authorization for the conduct of the Phase I clinical trial on February 16, 2017. Algorithme Pharma will be initiating the clinical trial activities in the coming weeks.

²We are very pleased to announce the authorisation of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

“This trial is part of Tetra’s commitment to develop medical Cannabis as a prescription drug for patients. The outcome of this trial is going to have significant implications in medical Cannabis research as it is a first pharmaceutical clinical trial assessing the effects of smoked Cannabis on cognitive function in healthy volunteers” said Mr. Rancourt, Chief Executive Officer

Earlier this month, Tetra and IntelGenx announced the co-development of Dronabinol AdVersa® Mucoadhesive controlled-release tablet for the management of Breakthrough Cancer Pain. The significant advantage of the Mucoadhesive technology was demonstrated in a Phase I clinical trial. The study demonstrated the delayed-release of THC avoids a rapid increase in the blood. ²With both of these products in clinical development, Tetra is on track with its objective to bring Cannabis-based prescription drugs to the market. Both of these products are promising alternatives in the battle for the reduction of opioids and improving quality of life in patients with chronic pain², added Dr. Chamberland.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Tags: , ,
Posted in Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on UPDATE: Tetra Bio-Pharma Reports Approval by Health Canada of its Phase I Trial of dried Cannabis $TBP.ca

Tetra Bio-Pharma Announces Approval by Health Canada of its Phase I Trial of dried Cannabis $TBP.ca

Posted by AGORACOM-JC at 12:39 PM on Thursday, February 16th, 2017

Tbp large

  • Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis
  • We are very pleased to announce the authorization of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

OTTAWA, ONTARIO–(Feb. 16, 2017) – PhytoPain Pharma Inc. (PPP), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that the Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis.

Tetra has worked with Algorithme Pharma, an Altasciences company, for the preparation of the Clinical Trial Application (CTA) for the conduct of a Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers. The CTA was submitted to Health Canada and the research ethics review board in December 2016. On January 3, 2017, the clinical trial received approval from the Institutional Review Board. TPD issued a Letter of Authorization for the conduct of the Phase I clinical trial on February 16, 2017. Algorithme Pharma will be initiating the clinical trial activities in the coming weeks.

²We are very pleased to announce the authorisation of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

“This trial is part of Tetra’s commitment to develop medical Cannabis as a prescription drug for patients. The outcome of this trial is going to have significant implications in medical Cannabis research as it is a first pharmaceutical clinical trial assessing the effects of smoked Cannabis on cognitive function in healthy volunteers” said Mr. Rancourt, Chief Executive Officer

Earlier this month, Tetra and IntelGenx announced the co-development of Dronabinol AdVersa® Mucoadhesive controlled-release tablet for the management of Breakthrough Cancer Pain. The significant advantage of the Mucoadhesive technology was demonstrated in a Phase I clinical trial. The study demonstrated the delayed-release of THC avoids a rapid increase in the blood. ²With both of these products in clinical development, Tetra is on track with its objective to bring Cannabis-based prescription drugs to the market. Both of these products are promising alternatives in the battle for the reduction of opioids and improving quality of life in patients with chronic pain², added Dr. Chamberland.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Tags: , , , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Announces Approval by Health Canada of its Phase I Trial of dried Cannabis $TBP.ca

Marijuana Company of America Transitions into Cultivation and Processing With New Agreement $MCOA.us

Posted by AGORACOM-JC at 8:51 AM on Wednesday, February 15th, 2017

15233 mcoa

  • Entered into a non-binding Letter of Intent  while performing due diligence to finalize a joint venture agreement with Bougainville Ventures, Inc.
  • For the purpose of housing tenant growers engaging in the cultivation, processing and commercial availability of legal marijuana in the State of Washington
  • MCOA will invest up to $1 million in cash in a newly formed entity and receive 50% equity ownership and 50% share in net profits produced by the joint venture
  • Bougainville Ventures, Inc. will contribute its expertise in establishing facilities related to the production, processing and management for tenant growers utilizing an I-502 Tier 3 license, with leased property, established partnerships, licensing agreements and marketing relationships

BONSALL, CA–(Feb 15, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company”) (OTC: MCOA), an innovative cannabis and hemp marketing and distribution Company, is pleased to announce that it has entered into a non-binding Letter of Intent (“LOI”) while performing due diligence to finalize a joint venture agreement with Bougainville Ventures, Inc. (“BV”) for the purpose of housing tenant growers engaging in the cultivation, processing and commercial availability of legal marijuana in the State of Washington.

Subject to the execution of a final definitive agreement, the terms of the LOI are that MCOA will invest up to $1 million in cash in a newly formed entity and receive 50% equity ownership and 50% share in net profits produced by the joint venture. Bougainville Ventures, Inc. will contribute its expertise in establishing facilities related to the production, processing and management for tenant growers utilizing an I-502 Tier 3 license, with leased property, established partnerships, licensing agreements and marketing relationships.

Donald Steinberg, MCOA President and CEO said, “We are looking forward to getting seed in the ground and ramping up this partnership with Andy Jagpal and Bougainville Ventures. This partnership further strengthens our supply chain and enables MCOA to produce the highest quality products at the lowest possible prices.”

“We couldn’t be happier than to have aligned ourselves with the outstanding team at MCOA,” said Jagpal, President of Bougainville Ventures, Inc. “With the management expertise that the highly skilled professionals at MCOA bring, we have insured the certainty of expanding our Washington State Greenhouse Campuses while achieving our revenue and profitability goals.”

This joint venture project is solely for the purpose of cultivation, processing and commercial availability of legal marijuana within the State of Washington only and not beyond its borders.

“As each new partnership is formed, synergistic benefits will develop organically,” said Steinberg. “Our human, agricultural and technical resources will expand with the end result being the ability to cultivate superior products for the cannabis consumer in each state in accordance with their respective laws.”

With more than half of the United States now allowing for some form of legal medicinal or recreational cannabis use, there is an urgent need to establish cutting edge cultivation facilities and programs to service the continually growing demand for cannabis and CBD products.

“Knowing how to manage the many individual cannabis markets effectively and simultaneously will be the key to success for MCOA’s national rollout,” said Steinberg. “By integrating and aggressively harnessing the collective resources of our companies, we are confident that we will be making a significant impact on sales and distribution in Washington State.”

ABOUT BOUGAINILLE VENTURES, INC.
Bougainville Venture Inc. is in the core business of converting irrigated farmland that was traditionally used to grow marginally profitable feed crops, to greenhouse-equipped farmland used to grow luxury crops with a primary focus on marijuana. Bougainville is an agricultural services company that focuses on providing growers with state-of-the-art computer controlled greenhouses and processing facilities. Bougainville offers fully built out turnkey solutions to licensed I-502 tenant-growers and luxury crop growers who will lease the facilities for production and processing. Bougainville does not “touch the plant” and only provides growing infrastructure as a landlord for licensed marijuana growers in the state of Washington. Bougainville has a strong management team with relevant experience and education in place with a focus on build-out and occupancy of its planned greenhouses in Oroville, WA. Strategic plans to expand its land bank, greenhouse campus and I-502 tenant-grower clients are scheduled for expanding operations.

SAFE HARBOR STATEMENT
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
888-777-4362
[email protected]

Tags: , ,
Posted in Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Marijuana Company of America Transitions into Cultivation and Processing With New Agreement $MCOA.us

Nazara Games will invest $20 million to build Indian esports league $GMBL.us

Posted by AGORACOM-JC at 9:28 AM on Tuesday, February 14th, 2017
Manish Agarwal, CEO, Nazara Games.
  • Nazara said it will invest the $20 million over the next five years in the league, which will be a subsidiary of Nazara Technologies

Nazara Games is announcing it will invest $20 million in a new esports league in India.

While Nazara Games is a mobile game publisher, the initial sports in the league will include PC-based games such as Dota 2 and Counter-Strike: Global Offensive. Nazara said it will invest the $20 million over the next five years in the league, which will be a subsidiary of Nazara Technologies.

Nazara Games recently reported a revenue of Rs 220 crore, or $26 million, and 40 percent compound annual growth rate for sales over the past four years. The company said it plans to build the “most vibrant and all-encompassing ecosystem for eSports in India, which can produce Indian teams capable of winning in global eSports competitions across different games.”

Nitish Mittersain, founder and managing director of Nazara Games, said in a statement, “Esports has become a cultural phenomenon in the last few years. Countries in Europe, Korea, China and US have seen massive growth in the number of players and spectators. Asia-Pacific accounts for 44 percent of the audience and is the fastest growing region globally. Given, improving internet connectivity in India today, launching an eSports league seemed the perfect way to reach out to the large group of esports enthusiasts in India.”

The league will have two seasons per year and will feature six teams that will be selected through open and free online qualifier tournaments. All players and teams from India are welcome to join this qualification process by following the online registration once the website has been launched. The progress of all players in the qualification tournament and their progress beyond can be tracked by the entire Indian esports community through live web programs.

Manish Agarwal, CEO of Nazara Games, said in a statement, “We are excited to provide Indian eSports enthusiasts with a solid and player/community orientated eSports ecosystem, in which players can thrive, improve their skills and become top competitors at an international level. The eSports league will not only be great for Indian players but also for fans. This platform will provide very extensive and exciting coverage of the Indian eSports landscape and will allow fans to track the careers and professional achievements of their eSport idols on a daily basis.”

Source: http://venturebeat.com/2017/02/13/nazara-games-will-invest-20-million-to-build-indias-esports-league/

Tags: , , , , ,
Posted in VGambling Inc. | Comments Off on Nazara Games will invest $20 million to build Indian esports league $GMBL.us

Tetra Discusses Clinical Program in New Interview with CFN Media

Posted by AGORACOM-JC at 9:19 AM on Tuesday, February 14th, 2017

Tbp large

  • Exclusive interview and article discussing the progress made by Tetra Bio-Pharma Inc. (OTC PINK: GRPOF) (CNSX: TBP) in its clinical trial program
  • Interview is with Dr. Guy Chamberland, Tetra’s Chief Science Officer

SEATTLE, WA–(Feb 14, 2017) – CFN Media Group (“CannabisFN”), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview and article discussing the progress made by Tetra Bio-Pharma Inc. (OTC PINK: GRPOF) (CNSX: TBP) in its clinical trial program. The interview is with Dr. Guy Chamberland, Tetra’s Chief Science Officer.

Medical marijuana may be legal for roughly 60% of the U.S. population, but the cost of the drug remains prohibitive for many patients in need. Tetra Bio-Pharma aims to undergo FDA-sanctioned clinical trials for dried medical marijuana to secure prescription drug coverage from insurance companies.

Tetra Bio-Pharma held a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) in late January to advance its PPP001 clinical trial. During the meeting, the FDA provided all the necessary guidance on the design of a Phase I clinical trial on healthy volunteers and its overall development program. The meeting further demonstrates the agency’s willingness to continue the clinical trial to develop a dried marijuana prescription drug.

PPP001 is a dried cannabis product with 9.5% tetrahydrocannabinol (“THC”) and 2% cannabidiol (“CBD”) that is being developed as a prescription drug that will meet the FDA’s high bar for quality and manufacturing. The company’s goal is to be the first to achieve reimbursement from insurance companies for the cost of the prescription, which could prove to be a game-changer for would-be medical marijuana patients that cannot afford the drug.

Tetra Bio-Pharma recently partnered with Sante Cannabis in Montreal to assist in developing its clinical trials. As a leading private medical marijuana clinic, the organization has years of experience in educating patients and ensuring the optimal benefits. The company aims to leverage this expertise to ensure that its clinical trials are properly designed to achieve desired outcomes while helping achieve the organization’s goal of lowering costs for patients.

Please follow the link to read the full article and see the interview: http://www.cannabisfn.com/tetra-bio-pharma-moves-closer-to-clinical-trials/

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:http://www.cannabisfn.com

About CFN Media

CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

CFN Media
Frank Lane
206-369-7050
[email protected]

 

Tags: , , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Discusses Clinical Program in New Interview with CFN Media

END OF DAY ALERT: (TBP: CSE) UP 38% ON 4.3M SHARES TRADED!

Posted by AGORACOM-JC at 5:05 PM on Monday, February 13th, 2017

TRADING ALERT!!!

TBP: CSE UP 38% ON 4.3M SHARES TRADED!

Tbp large

Close: $0.79 Up: $0.22

Percentage: +38% Volume: 4.3M Shares

Hub On AGORACOM

Tags: , , ,
Posted in Tetra Bio-Pharma Inc. | Comments Off on END OF DAY ALERT: (TBP: CSE) UP 38% ON 4.3M SHARES TRADED!

« Older Entries
Newer Entries »